Pemetrexed: A review of its use in the management of advanced non-squamous non-small cell lung cancer

Drugs

Volumn 69, Issue 16, 2009, Pages 2279-2302

  Baldwin, Claudine M ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEMCITABINE; IBUPROFEN; OXALIPLATIN; PEMETREXED; PLACEBO;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HOSPITALIZATION; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PHARYNGITIS; REVIEW; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 70350521064     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202640-000000000-00000     Document Type: Review

References (78)

1. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl. 4: iv68-70
2. National Cancer Institute. Surveillance epidemiology and end results (SEER) stat fact sheets [online]. Available from URL: http://seer.cancer.gov/ statfacts/html/lungb.html [Accessed 2009 Jul 9]
3. Stinchcombe TE, Socinski MA. Current treatments for ad-vanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009; 6 (2): 233-241
4. Eli Lilly and Company. About lung cancer [online]. Avail-able from URL: http://www.gemzar.com/pat/pat110- types-of-nsclc.jsp [Accessed 2009 May 21]
5. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009 Mar; 14 (3): 253-263
6. Alberts WM. Diagnosis and management of lung cancer: executive summary. Chest 2007; 132 Suppl.: 1-19
7. National Institute for Clinical Excellence. The diagnosis and treatment of lung cancer: methods, evidence & guidance [online]. Available from URL: http://www.nice.org.uk/ nicemedia/pdf/cg024fullguideline.pdf [Accessed 2009 Jul 22]
8. European Medicines Agency. Pemetrexed: ALIMTA 100mg powder for concentrate for solution for infusion: scientific discussion [online]. Available from URL: http:// www.emea.europa.eu/humandocs/PDFs/EPAR/alimta/ 102004en6.pdf [Accessed 2009 Apr 27]
9. European Medicines Agency. ALIMTA 100mg powder for concentrate for solution for infusion: summary of product characteristics [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/alimta/H-564-PI-en.pdf [Accessed 2009 Apr 27] 10. Eli Lilly and Company. ALIMTA (pemetrexed disodium) injection, powder, lyophillized, for solution for intravenous use: US prescribing information [online]. Available from URL: http://pi.lilly.com/us/ alimta-pi.pdf [Accessed 2009 Jul 20]
10. Eli Lilly and Company. Lilly receives fourth FDA approval as maintenance therapy for nonsquamous non-small cell lung cancer [media release]. 2009
11. Latz JE, Chaudhary A, Ghosh A, et al. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006; 57: 401-411
12. Robinson DM, Keating GM, Wagstaff AJ. Pemetrexed: a review of its use in malignant pleural mesothelioma and non-small-cell lung cancer. Am J Cancer 2004; 3 (6): 387-399
13. Swainston Harrison T, Scott LJ. Pemetrexed. Am J Cancer 2003; 2 (5): 359-370
14. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007 Feb; 6 (2): 404-417
15. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997 Mar 15; 57 (6): 1116-1123
16. Racanelli AC, Rothbart SB, Heyer CL, et al. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation and mammalian target or rapamycin inhibition. Cancer Res 2009; 69 (13): 5467-5474
17. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127: 917-928
18. Zhao R, Qiu A, Tsai E, et al. The proton-coupled folate transporter: impact on pemetrexed transport and on anti-folates activities compared with the reduced folate carrier. Mol Pharm 2008; 74 (3): 854-862
19. Habeck LL, Mendelsohn LG, Shih C, et al. Substrate spe-cificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995 Aug; 48 (2): 326-333
20. Britten CD, Izbicka E, Hilsenbeck S, et al. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 1999; 44 (2): 105-110
21. Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites; implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521-531
22. Tonkinson JL, Worzalla JF, Teng C-H, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcita-bine in HT29 colon carcinoma. Cancer Res 1999 Aug; 59: 3671-3676
23. Teicher BA, Chen V, Shih C, et al. Treatment regimens in-cluding the multitargeted antifolate LY231514 in human tumor xenografts. Clin Can Res 2000 Mar; 6: 1016-1023
24. Li T, Ling YH, Goldman ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007 Jun 1; 13 (11): 3413-3422
25. Giovannetti E, Lemos C, Tekle C, et al. Molecular me-chanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008 Apr; 73 (4): 1290-1300
26. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22: 7431-7457
27. Andreassi JL, Moran RG. Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry (Mosc) 2002; 41 (1): 226-235
28. Chattopadhyay S, Zhao R, Krupenko SA, et al. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006; 5 (2): 438-449
29. Dickgreber NJ, Diaz Padilla I, Paz-Ares LG, et al. The safety and pharmacokinetics (PK) of pemetrexed (PEM) in patients with third-space fluid (TSF) [abstract no. 2555]. J Clin Oncol 2008; 26 (15 Suppl.)
30. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 Jul 20; 26 (21): 3543-3551
31. Cullen MH, Zatloukal P, Sorenson S, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008; 19: 939-945
32. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 May 1; 22 (9): 1589-1597
33. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. In press
34. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11: 435-440
35. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma. Cancer 2001; 92 (3): 595-600
36. Smit EF, Mattson K, von Pawel J, et al. ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003; 14: 455-460
37. US FDA. Center for Drug Evaluation and Research. Application number: 21-677 medical review [online]. Available from URL: http://www.accessdata.fda. gov/ drugsatfda-docs/nda/2004/021677s000-Alimta-MedR.pdf [Accessed 2009 Jul 10]
38. Hollen P. Lung cancer symptom scale (LCSS) [online]. Available from URL: http://www.lcss-ql.com/ [Accessed 2009 Apr 28]
39. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract no. P2-328]. J Thor Oncol 2007 Aug; 2 (8 Suppl. 4): S851
40. Pimentel FL, von Pawel J, Martins RG, et al. Resource utilization by non-small cell lung cancer histology: results from the randomized, phase III trial of pemetrexed/ cisplatin versus gemcitabine/cisplatin [abstract no. 8097]. J Clin Oncol 2008; 26 (15 (Suppl.)
41. Muehlenbein CE, Klein RW, Liepa AM, et al. The impor-tance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancer [abstract no. e17533]. J Clin Oncol 2009; 27 Suppl.
42. Wielage R, Muehlenbein C, Liepa AM, et al. The budgetary impact of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer (NSCLC) [abstract no. PCN 20]. International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; 2009 May 16-20; Orlando, FL
43. Scottish Medicines Consortium. Pemetrexed, 100 mg, 500 mg powder for concentrate for solution for infusion (Alimta®) [online]. Available from URL: http://www. scottishmedicines.org.uk/smc/files/pemetrexed%20Alimta% 20FINAL%20January%202009%20for%20website.pdf% 2016.02.09.pdf [Accessed 2009 Jul 21]
44. Bushill-Matthews L, Jackson D, Aristides M, et al. Redu-cing health care burden for the treatment of toxicity associated with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer who previously received chemotherapy: application to the UK setting [abstract no. 769]. Eur J Cancer 2003; 1 (5 Suppl.): S231
45. Stynes G, Aristides M, Rosell R, et al. Improved toxicity profile of pemetrexed vs docetaxel in previously treated non-small cell lung cancer patients translates to cost savings in Spain [abstract no. PCN30]. International Society for Pharmacoeconomics and Outcomes Research European Congress; 2004 Oct 24-26; Hamburg
46. Pavlakis N, Mitchell PL, Stynes G, et al. Cost effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer [abstract no. 6084]. J Clin Oncol 2005; 23 (16 Suppl.)
47. Brown A, Aristides M, Fitzgerald P, et al. Patient preference and willingness-to-pay for pemetrexed versus docetaxel in the second-line treatment of advanced non-small cell lung cancer: a discrete choice conjoint analysis [abstract no. PCN7]. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference; 2006 Mar 5-7; Shanghai
48. Bhalla S, Hibbert C, Watkins J, et al. To determine the cost-effectiveness of pemetrexed compared to current standards of care in 2nd-line advanced non-small cell lung cancer from the UK National Health Service perspective [abstract no. 6540]. J Clin Oncol 2007; 25 (18 Suppl.): 332
49. National Institute for Health and Clinical Excellence. Pe-metrexed for the treatment of non-small-cell lung cancer: NICE technology appraisal guidance 124 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ TA124Guidance.pdf [Accessed 2009 Jul 16]
50. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008 Sep; 61 (3): 405-415
51. Chouaid C, Atsou K, Hejblum G, et al. Economics of treatment for non-small cell lung cancer. Pharmaco-economics 2009; 27 (2): 113-125
52. Esteban E, Casillas M, Cassinello A. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev 2009; 35 (4): 364-373
53. National Cancer Institute. Non-small cell lung cancer treat-ment [online]. Available from URL: http://www.cancer. gov/cancertopics/pdq/treatment/ non-small-cell-lung/health professional [Accessed 2009 Jun 2]
54. Pfister DG, Johnson DH, Azzoli CG, et al. American So-ciety of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22 (2): 330-353
55. National Comprehensive Cancer Network. NCCN practice guidelines in oncology-v.2. 2009: non-small cell lung cancer [online]. Available from URL: http://www.nccn.org/ professionals/physician-gls/PDF/nscl.pdf [Accessed 2009 Jul 21]
56. Scottish Intercollegiate Guidelines Network. Management of patients with lung cancer: quick reference guide [online]. Available from URL: http://www.sign.ac.uk/pdf/ qrg80.pdf [Accessed 2009 Jul 22]
57. National Institute for Health and Clinical Excellence. Pe-metrexed for the first-line treatment of non-small-cell lung cancer: NICE technology appraisal guidance 181 [online]. Available from URL: http://www.nice.org.uk/ nicemedia/ pdf/TA181Guidance.pdf [Accessed 2009 Sep 28]
58. Scottish Medicines Consortium. SMC accepts restricted use of pemetrexed (Alimta) in locally advanced or metastatic NSCLC (resubmission) [online]. Available from URL: http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific- Reviews/SMC-accepts-restricted-use-of-pemetrexed-Alimta-in-locally-advanced-or- metastatic-NSCLC-resubmission [Accessed 2009 Aug 17]
59. Stinchcombe TE, Socinski MA. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 2009; 4 (2): 243-250
60. Ramalingam S, Belani C. Systemic chemotherapy for ad-vanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; 13 Suppl. 1: 5-13
61. National Cancer Institute. New lung cancer treatment hope raises hopes and debates [online]. Available from URL: http://www.cancer.gov/ ncicancerbulletin/072809/page5 [Accessed 2009 Oct 7]
62. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carci-noma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107 (7): 1589-1596
63. Bergqvist M, Henriksson R, Brattstrom D. Novel agents in the treatment of non-small cell lung cancer: implications for neoadjuvant chemotherapy? In Vivo 2005; 19 (3): 523-533
64. Monahan BP, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, editors. Cancer chemotherapy & biotherapy: principles and practice. 4th ed. Philadelphia (PA): Lippin-cott Williams & Wilkins, 2005: 96
65. Bergqvist M, Sorenson S, Brattstrom D, et al. Role of non-taxane-containing chemotherapy in advanced non-small cell lung cancer. Am J Cancer 2006; 5 (4): 223-244
66. Monnerat C, Le Chevalier T. Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 2006; 17 Suppl. 5: v86-90
67. Vokes EE, Senan S, Treat JA, et al. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009;10(3): 193-198
68. US National Institutes of Health. Evaluation of pemetrexed combined with cisplatin and radiotherapy for unresectable locally advanced non-small cell lung cancer (NSCLC) (PACCORA) [online]. Available from URL: http:// www.clinicaltrials.gov/ct2/show/NCT00497315 [Accessed 2009 Jul 23]
69. US National Institutes of Health. Chemotherapy and radia-tion in treating patients with stage 3 non-small cell lung cancer (PROCLAIM) [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00686959 [Accessed 2009 Jul 23]
70. De Boer R, Arrieta O, Gottfried FH, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL) [abstract no. 8010]. J Clin Oncol 2009; 27 (15 Suppl.)
71. US National Institutes of Health. A study of induction and maintenance treatment of advanced non-squamous non small cell lung cancer [online]. Available from URL: http:// www.clinicaltrials.gov/ct2/show/NCT00789373 [Accessed 2009 Aug 20]
72. Patel JD, Bonomi P, Socinksi MA, et al. Treatment rationale and study design for the PointBreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/ bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small cell lung cancer. Clin Lung Cancer 2009; 10 (4): 252-256
73. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008; 13 Suppl. 1: 28-36
74. Sanofi-Aventis. Taxotere® (docetaxel) injection concentrate: US prescribing information [online]. Available from URL: http://products.sanofi- aventis.us/Taxotere/taxotere.html [Accessed 2009 May 20]
75. Russo F, Bearz A, Pampaloni G, et al. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 2008 Jul; 8: 216
76. Eli Lilly and Company. GEMZAR® (gemcitabine HCl) for injection: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2006/ 020509s039lbl.pdf [Accessed 2009 May 20]
77. Electronic Medicines Compendium. Iressa 250 mg film-coated tablets [online]. Available from URL: http:// www.emc.medicines.org.uk/medicine/22104/ SPC/Iressa% 20250 mg%20film-coated%20tablets/#INDICATIONS [Accessed 2009 Jul 28]
78. AstraZeneca. Iressa (RM) gefitinib tablets 250mg: UK prescribing information [online]. Available from URL: http://www1.astrazeneca-us.com/PI/ iressa.pdf [Accessed 2009 Jul 28]